Extracorporeal photopheresis: what is it and when should it be used?
- 1 October 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 34 (7) , 757-760
Abstract
Extracorporeal photopheresis (ECP) is a technique that was developed > 20 years ago to treat erythrodermic cutaneous T-cell lymphoma (CTCL). The technique involves removal of peripheral blood, separation of the buffy coat, and photoactivation with a photosensitizer and ultraviolet A irradiation before re-infusion of cells. More than 1000 patients with CTCL have been treated with ECP, with response rates of 31-100%. ECP has been used in a number of other conditions, most widely in the treatment of chronic graft-versus-host disease (cGvHD) with response rates of 29-100%. ECP has also been used in several other autoimmune diseases including acute GVHD, solid organ transplant rejection and Crohn's disease, with some success. ECP is a relatively safe procedure, and side-effects are typically mild and transient. Severe reactions including vasovagal syncope or infections are uncommon. This is very valuable in conditions for which alternative treatments are highly toxic. The mechanism of action of ECP remains elusive. ECP produces a number of immunological changes and in some patients produces immune homeostasis with resultant clinical improvement. ECP is available in seven centres in the UK. Experts from all these centres formed an Expert Photopheresis Group and published the UK consensus statement for ECP in 2008. All centres consider patients with erythrodermic CTCL and steroid-refractory cGvHD for treatment. The National Institute for Health and Clinical Excellence endorsed the use of ECP for CTCL and suggested a need for expansion while recommending its use in specialist centres. ECP is safe, effective, and improves quality of life in erythrodermic CTCL and cGvHD, and should be more widely available for these patients.Keywords
This publication has 26 references indexed in Scilit:
- A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host diseaseBlood, 2008
- U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host diseaseBritish Journal of Dermatology, 2008
- EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndromeEuropean Journal of Cancer, 2006
- Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma GroupBritish Journal of Dermatology, 2005
- Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factorsBone Marrow Transplantation, 2005
- Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell LymphomaJournal of Cutaneous Medicine and Surgery, 2003
- Treatment of Cutaneous T-Cell Lymphoma With Combined Immunomodulatory TherapyArchives of Dermatology, 2002
- Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: A prospective controlled trialJournal of the American Academy of Dermatology, 2001
- Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institutionJournal of the American Academy of Dermatology, 1996
- Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal PhotochemotherapyNew England Journal of Medicine, 1987